Skip to Content


In the US, Carfilzomib (carfilzomib systemic) is a member of the drug class proteasome inhibitors and is used to treat Multiple Myeloma.

US matches:



CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Categories

Antineoplastic agent

Proteasome inhibitor

Chemical Name

{(2S)-2-[(morpholin-4-yl)acetamido]-4-phenylbutanoyl}-L-leucyl-N¹-{(2S)-1-[(2R)-2-metyloxiran-2-yl]-4-metyl-1-oxopentan-2-yl}-L-phenylalaninamide (WHO)

Foreign Names

  • Carfilzomibum (Latin)
  • Carfilzomib (German)
  • Carfilzomib (French)
  • Carfilzomib (Spanish)

Generic Names

  • Carfilzomib (OS: USAN, JAN)
  • PR-171 (IS)
  • UNII-72X6E3J5AR (IS)

Brand Names

  • Kyprolis
    Amgen, Germany; Amgen, United Kingdom; Amgen Europa, Israel; Amgen Switzerland, Switzerland; Onyx Pharmaceuticals, United States

International Drug Name Search


ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.